Methods	Six-week randomised, double-blind multicentre study.
Participants	Outpatients fulfilling DSM-III criteria for major depressive disorder (with a duration of illness of at least 4 weeks), with a score of at least 20 on the HDRS-21 and a score of at least 8 on the Raskin. Age range: 18-70 years old. Exclusion criteria: not stated.
Interventions	Fluoxetine: 185 participants. Imipramine: 186 participants. Placebo: 169 participants. Fluoxetine dose range: 20-80 mg/day. Imipramine dose range: 75-300 mg/day.
Outcomes	Hamilton Rating Scale for Depression, Raskin Depression Scale, Covi Anxiety Scale, CGI-I and CGI-S
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear